Financial experts break down what you need to earn to afford a median-priced home in the United States.
Shares of Israeli container shipping company ZIM Integrated Shipping Services (NYSE: ZIM) tumbled 3.4% through 11:05 a.m. EST Monday -- and it's no huge secret why. Across the shipping world, stocks including ZIM, Costamere, and Danaos Corporation are all sliding today. As multiple media outlets have reported, protests against a government "zero-Covid" policy are spreading across China, threatening both the ruling regime's stability, the country's economy, and its ability to produce products that would need container shipping services to reach foreign markets.
Investors looking for a guiding hand to steer them safely through the current hazardous stock market landscape could do worse than listen to what billionaire Ken Fisher has to say. The Fisher Investments founder famously started his independent money management firm with $250 in 1979, a company that is now a $197-plus billion going concern, while Fisher’s own net worth stands north of $5 billion. So, for those getting restless from 2022’s unrelenting bear, Fisher has some very simple advice: "Th
With a yield of 9.62%, the recently expired Series I bond was understandably popular. With interest rates rising, bond funds are down this year and banks continue to offer miserly rates on deposit accounts. So it's no wonder that a … Continue reading → The post It Pays to Procrastinate: The New 6.89% I bonds Will Beat the Old 9.62% Bonds in Just 4 Years appeared first on SmartAsset Blog.
Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen this week.
In this article, we will discuss the best dividend stocks according to hedge funds with over 5% yield. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best 5% Dividend Stocks To Buy According To Hedge Funds. The current stock market situation has […]
What happened Shares of Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biotech that specializes in therapies to treat neurodegenerative and neurodevelopmental diseases, fell by 23.5% on Monday.
The abrupt and rapid collapse of the FTX cryptocurrency exchange has caused a shock in the crypto space. The fall, in a few days, of a company valued at $32 billion in February, ended up casting suspicion on the entire young industry of financial services, based on the Blockchain technology. Retail investors have fled, while institutional investors, linked to FTX and its sister company Alameda Research, are still determining their losses from their exposure to Sam Bankman-Fried's empire.
Shares of leading semiconductor companies Taiwan Semiconductor Manufacturing (NYSE: TSM), Intel (NASDAQ: INTC), and Qualcomm (NASDAQ: QCOM) all fell today, declining 2.9%, 2.6%, and 3.6%, respectively, as of 3:37 p.m. ET. First, widespread protests in China over COVID-19 restrictions erupted this past weekend, putting pressure on any stock with exposure to China or products made there. Second, a report from a leading tech industry research company predicted a bigger decline in overall semiconductor revenue next year than it had forecast just four months ago.
In this article, we discuss the top 10 stock picks from Louis Navellier. If you want to see more stocks in this selection, check out Louis Navellier’s Top 5 Stock Picks for Q4 2022. Louis Navellier, the author of a BusinessWeek best-seller, “The Little Book That Makes You Rich”, is the founder and chairman of […]
Financial services are one of the world's largest industries, worth trillions of dollars. Financial technology companies like SoFi Technologies (NASDAQ: SOFI) are trying to do things differently and, as a result, are nipping at the heels of traditional banks. Here is why SoFi's stock could shine like a diamond in 2023.
In this article, we will be taking a look at 10 Robinhood stocks to buy that are too cheap to ignore. To skip our detailed analysis of these stocks, you can go directly to see the 5 Robinhood Stocks To Buy That Are Too Cheap To Ignore. Robinhood, a commission-free stock trading and investing company, has […]
Tesla stock is on the rise in early trade despite a broader market selloff and general weakness in the stock lately. Here’s what’s moving Tesla today.
(Bloomberg) -- Federal Reserve policymakers stressed on Monday that they will raise borrowing costs further to curb inflation, with one key official saying that he sees interest rates heading somewhat higher than he had forecast just a couple of months ago.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsThere’s a Job-Market Riddle at the Heart of the Next Recession“Stronger demand for labor, stronger
Some investors are focusing on the fact that the EV stock is at the lowest level in more than two years.
Energy is everywhere, in everything we do; we can’t avoid it. The sheer ubiquity of the sector is one major factor drawing investors to it. After all, energy companies will always be able to find customers for their products, and will never lack for sales. Energy companies have also been seen as a hedge against inflation. The energy sector has been riding high this year, with the S&P 500 energy index up 61% year-to-date. So the question for investors is, do energy stocks have more room to run? A
Axsome Therapeutics said its Alzheimer's treatment met the goals of a study, sending its shares into the stratosphere, while Biogen's Alzheimer's effort had a setback.
The dispute between the world's richest man and the world's biggest corporation spills into the open.
The FTX bankruptcy has hurt many stocks in the crypto space, creating buying opportunities for those who are brave enough.
Axsome Therapeutics Inc's (NASDAQ: AXSM) AXS-05 substantially and statistically significantly delayed the time to relapse and prevented relapse of agitation in patients with Alzheimer's disease, compared to placebo. The ACCORD Phase 3 trial represented a 3.6-fold lower relapse risk than the placebo. AXS-05 also met the key secondary endpoint of relapse prevention based on the relapse rates during the double-blind treatment period (7.5% of AXS-05 patients vs. 25.9% of placebo patients). Related: